Currently Viewing:
Newsroom
Currently Reading
A New Treatment Option for Newly Diagnosed AML: Gemtuzumab Ozogamicin
September 01, 2017 – AJMC Staff
This Week in Managed Care: September 1, 2017
September 01, 2017
FDA Emphasizes Risks of Pembrolizumab in Multiple Myeloma After Reviewing Halted Trials
September 01, 2017 – Christina Mattina
Pembrolizumab Plus Epacadostat Yields Durable Response in Advanced Melanoma: ESMO
August 31, 2017 – Surabhi Dangi-Garimella, PhD
Once-Daily Treatment for ADHD in Adults Launched in the United States
August 31, 2017 – Laura Joszt
Abeona Receives Breakthrough Designation for Rare Skin Disease Gene Therapy
August 31, 2017 – AJMC Staff
What We're Reading: Dialysis After Harvey; Inflammation Research; Youth Exercise Benefits Adult Brain
August 31, 2017 – AJMC Staff
Race, Socioeconomic Status Linked to Rehospitalizations Among Patients With Advanced Cancer
August 30, 2017 – Christina Mattina
FDA Approves Tisagenlecleucel, the First CAR-T Cell Therapy in the United States
August 30, 2017 – Laura Joszt

A New Treatment Option for Newly Diagnosed AML: Gemtuzumab Ozogamicin

AJMC Staff
The treatment, which was approved nearly 2 decades ago but withdrawn due to safety and efficacy concerns, now has a new indication.
A drug that was approved nearly 2 decades ago now has a new indication. Today’s FDA approval means patients with newly diagnosed CD33-positive acute myeloid leukemia (AML) and patients 2 years and older with relapsed/refractory CD33-positive AML can now be treated with gemtuzumab ozogamicin (Mylotarg).

Safety concerns and lack of clinical benefit in confirmatory trials had resulted in the drug’s withdrawal from the market following its accelerated approval back in May 2000. The drug now has a reduced dose, can be administered alone or has a different schedule with combination chemotherapy, and also has a different patient population.

“We are approving Mylotarg after a careful review of the new dosing regimen, which has shown that the benefits of this treatment outweigh the risk,” said Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Mylotarg’s history underscores the importance of examining alternative dosing, scheduling, and administration of therapies for patients with cancer, especially in those who may be most vulnerable to the side effects of treatment.”

The trial in 271 patients with newly diagnosed CD33-positive AML randomized patients to receive daunorubicin and cytarabine with or without Mylotarg. Event-free survival was better among patients who received the experimental drug (17.3 months vs 9.5 months). Additionally, in a separate trial, patients who received Mylotarg survived longer (median overall survival [OS], 4.9 months) compared with the control arm (median OS, 3.6 months).

Common side effects of Mylotarg include pyrexia, nausea, infection, vomiting, bleeding, thrombocytopenia, stomatitis, constipation, rash, headache, elevated liver function tests, and neutropenia. Severe side effects of Mylotarg include low blood counts, infections, liver damage, hepatic veno-occlusive disease, infusion-related reactions, and hemorrhage.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up